MONISTAT 1 COMBINATION PACK OTC
Generic Name and Formulations:
Miconazole 1200mg (vaginal supp), miconazole nitrate 2% (topical crm).
Indications for MONISTAT 1 COMBINATION PACK:
Insert 1 supp vaginally once at bedtime. Crm: apply twice daily as needed for up to 7 days.
Use of contraceptive diaphragm or condoms within 3 days, or use of tampons, douches, or spermicides within 7 days: not recommended. Confirm diagnosis by KOH smears +/or cultures. If ineffective, reconfirm diagnosis before repeating therapy. Discontinue if irritation occur. 1st trimester of pregnancy. Nursing mothers.
May potentiate warfarin.
Vulvovaginal burning, itching or irritation; edema, cramps, nausea, headache, rash, urticaria.
Combination Pack—1x1200mg supp (w. applicator or prefilled applicator) + 9g topical crm
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|